Results 191 to 200 of about 107,178 (262)

Mapping the Global Clinical Landscape of Pharmacological Therapies for Heart Failure With Preserved Ejection Fraction: An Analysis Based on ClinicalTrials.gov (2003–2025)

open access: yesiMetaMed, EarlyView.
This study analyzed 236 heart failure with preserved ejection fraction (HFpEF) pharmacological trials registered on ClinicalTrials.gov from 2003 to 2025, revealing a post‐2016 surge (76.3%), U.S. dominance (58.5%), and prominence of SGLT2 inhibitors/novel therapies (each 13.1%).
Yucheng Hou   +6 more
wiley   +1 more source

A New Paradigm: 46 Structural Cell Types Function as Environment‐Supporting Innate Immune Cells, With Endothelial and Vascular Smooth Muscle Cells as Key Prototypes

open access: yesiNew Medicine, EarlyView.
ABSTRACT The scope, organization, and biological significance of innate immune functions across structural cell types remain poorly defined. To address these fundamental knowledge gaps, we analyzed experimental data of transcriptomes generated by our group and others.
Juanjuan Liu   +22 more
wiley   +1 more source

Characterization of elevated levels of endometrial renin-angiotensin system components suggest a role in endometrial repair. [PDF]

open access: yesFront Endocrinol (Lausanne)
Symington TL   +6 more
europepmc   +1 more source

The Role of β-Blockers in the Evolving Treatment Landscape of Resistant Hypertension. [PDF]

open access: yesDrugs
Masi S   +7 more
europepmc   +1 more source

The role of IP<sub>3</sub>R and TRPC3 channels in vasoconstriction and hypertension. [PDF]

open access: yesPflugers Arch
Moraes RDA   +4 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy